Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung function with high mortality within the first 5 years from diagnosis. In 2011–2014, two drugs, pirfenidone and nintedanib, have been approved worldwide for prevention of IPF progression. National IPF-registr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Multidiscip Respir Med
Egile Nagusiak: Pesonen, Ida, Carlson, Lisa, Murgia, Nicola, Kaarteenaho, Riitta, Sköld, Carl Magnus, Myllärniemi, Marjukka, Ferrara, Giovanni
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2018
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5950183/
https://ncbi.nlm.nih.gov/pubmed/29785264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40248-018-0126-7
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak